27/10/2025
GPN Vaccines Inc Completes Acquisition of BacVax Inc.
New York, USA – 24th October 2025 GPN Vaccines Inc (“GPN”) is pleased to announce it has successfully…
News
- Read article
19/09/2025GPN Vaccines announces changes to its Board of Directors
Read articleNew York, USA – 19th September 2025 GPN Vaccines Inc (USA) today announces the retirement of Prof. James…
08/09/2025GPN Vaccines receives $4.7 million R&D Tax Incentive refund
Read articleNew York, USA – 8th September 2025 GPN Vaccines is pleased to announce it has received AU$4.7 million…
25/07/2025GPN Vaccines Inc Acquires GPN Vaccines Ltd
Read articleNew York, USA and Adelaide, Australia – 25th July 2025 GPN Vaccines Inc, a Delaware C-corporation, formally announces…
14/07/2025GPN Vaccines reports strong immunogenicity data in older adults independent of previous pneumococcal vaccination status with good tolerability and sustained immunogenicity
Read articleAdelaide, Australia, 14th July 2025 GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to…
12/06/2025Notice to Scheme Shareholders
Read articleOn 12 June 2025, GPN AUS and GPN USA signed a Deed of Variation to the Scheme Implementation…
- 27/05/2025
GPN Vaccines Shareholders Vote in Favour of Re-domiciliation of the Company to the United States of America; Notice of Hearing to Approve Scheme of Arrangement
Read articleCanberra, Australia, 27th May 2025 GPN Vaccines Ltd is pleased to announce the Company’s shareholders have voted unanimously…
- 12/11/2024
Dose Escalation Approved and Dosing Commenced in Second Cohort of GPN Vaccines’ Phase 1 Clinical Trial in Older Adults
Read articleAdelaide, Australia, 12 th November 2024 – GPN Vaccines Ltd is pleased to announce that dose escalation has…
17/10/2024GPN Vaccines Welcomes Dr. Bruce Forrest as Chief Scientific Officer
Read articleAdelaide, Australia, 17th October 2024 – GPN Vaccines Ltd is thrilled to announce the appointment of Dr. Bruce…
04/09/2024First Participant Dosed in Phase 1 Clinical Trial of Gamma-PN in Older Adults
Read articleAdelaide, Australia, 5th September 2024 – GPN Vaccines Ltd is pleased to announce that the first participant has…
21/08/2024GPN Vaccines Secures Ethics Approval for a Clinical Trial of its Pneumococcal Vaccine in Older Adults
Read articleAdelaide, Australia, 21st August 2024 GPN Vaccines is pleased to announce it has received ethics approval to commence…
05/06/2024GPN Vaccines Closes $18M Series B1 Round
Read articleAdelaide, Australia, 6th June 2024 – GPN Vaccines is pleased to announce the closing of its oversubscribed Series…